Evotec AG and Second Genome, Inc. have formed a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimization of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome’s approach to identify and modulate microbiome-mediated pathways will be enhanced by the use and the results of Evotec’s integrated drug d...